Literature DB >> 8239543

p53 gene mutation spectrum in human unknown primary tumors.

M Bar-Eli1, J L Abbruzzese, D Lee-Jackson, P Frost.   

Abstract

Mutations affecting the p53 gene are associated with many human malignancies, but little is known about changes in p53 in unknown primary tumors (UPTs), which are characterized as tumors with advanced stages of malignancy. We therefore investigated the frequency of p53 mutations in a series of 15 unknown primary tumor biopsies and eight cell lines established from UPTs. Mutations in the conserved regions of the p53 gene were verified by single-strand conformation polymorphism analysis of exons 5-9 and were verified by direct DNA sequencing of polymerase chain reaction products. A point mutation leading to an amino acid change in the p53 protein was found in six cases, and a mutation causing a change to termination was found in one case. A frameshift mutation was observed in one cell line. In one patient and one cell line we observed more than one mutation in the p53 coding sequence. Overall, the frequency of mutations that changed the p53 coding sequence in the UPTs we studied was 26% (6/23). Mutations were distributed in eight codons of the p53 gene. Seven of these tumors showed a reduction to homozygosity at the p53 allele, but one tumor apparently retained heterozygosity. We conclude that although UPTs represent highly metastatic advanced tumors that are expected to have a high incidence of p53 mutations, the frequency of p53 mutations is relatively low, suggesting that p53 mutations may not play a major role in the development and progression of this unique tumor type.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8239543

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  12 in total

1.  Cytogenetic profile of unknown primary tumors: clues for their pathogenesis and clinical management.

Authors:  Dimitra Pantou; Haroula Tsarouha; Anna Papadopoulou; Louiza Mahaira; Ioannis Kyriazoglou; Nikiforos Apostolikas; Sophia Markidou; Theoni Trangas; Nikos Pandis; Georgia Bardi
Journal:  Neoplasia       Date:  2003 Jan-Feb       Impact factor: 5.715

Review 2.  Carcinoma of unknown primary with hepatic metastases: a need of judicious and contemplative diagnostic algorithm.

Authors:  Vikram Sai Shivaji; Joseph Charles Wilson; Noemi L Schmidt; Orpheus Kolokythas; Neeraj Lalwani
Journal:  Abdom Radiol (NY)       Date:  2020-07-06

Review 3.  [Metastases with CUP syndrome].

Authors:  S Seeber; D Strumberg
Journal:  Urologe A       Date:  2006-05       Impact factor: 0.639

4.  [Cancer of unknown primary. Epidemiology and pathogenesis].

Authors:  H Löffler; K Neben; A Krämer
Journal:  Radiologe       Date:  2014-02       Impact factor: 0.635

5.  Metastases in the Absence of a Primary Tumor: Advances in the Diagnosis and Treatment of CUP Syndrome.

Authors:  Kai Neben; Gerdt Hübner; Gunnar Folprecht; Dirk Jäger; Alwin Krämer
Journal:  Dtsch Arztebl Int       Date:  2008-10-24       Impact factor: 5.594

6.  Carcinoma of unknown primary origin.

Authors:  Gauri R Varadhachary
Journal:  Gastrointest Cancer Res       Date:  2007-11

7.  [CUP syndrome: molecular pathogenesis and biology].

Authors:  A Krämer; S Gattenlöhner; K Neben
Journal:  Pathologe       Date:  2009-03       Impact factor: 1.011

Review 8.  Cancers of unknown primary origin: current perspectives and future therapeutic strategies.

Authors:  Giulia Maria Stella; Rebecca Senetta; Adele Cassenti; Margherita Ronco; Paola Cassoni
Journal:  J Transl Med       Date:  2012-01-24       Impact factor: 5.531

9.  Biological characterization of two xenografts derived from human CUPs (carcinomas of unknown primary).

Authors:  Delphine Lequin; Karim Fizazi; Saloua Toujani; Sylvie Souquère; Marie-Christine Mathieu; Pierre Hainaut; Alain Bernheim; Françoise Praz; Pierre Busson
Journal:  BMC Cancer       Date:  2007-12-18       Impact factor: 4.430

10.  Carboplatin, doxorubicin and etoposide in the treatment of tumours of unknown primary site.

Authors:  A Piga; R Nortilli; G L Cetto; N Cardarelli; S Luzi Fedeli; G Fiorentini; M D'Aprile; F Giorgi; A P Parziale; A Contu; R Montironi; R Gesuita; F Carle; R Cellerino
Journal:  Br J Cancer       Date:  2004-05-17       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.